Literature DB >> 18032598

Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus.

Eiji Konishi1, Yoko Kitai, Takashi Kondo.   

Abstract

Enzyme-linked immunosorbent assay (ELISA) and related assays are representative of methods currently used for antibody tests. However, they occasionally produce nonspecific reactions, thus making it difficult to reliably measure low levels of specific antibodies. To find a test method that minimizes nonspecific reactions, we introduced the principle of antibody-mediated complement-dependent cytotoxicity (CDC) into an antibody assay. The procedure has three steps: (i) the mixing of test samples with a suspension of cells expressing the antigen of interest on their surfaces, (ii) the addition of rabbit complement, and (iii) the measurement of lactose dehydrogenase (LDH) activities by adding a chromogenic substrate to the reaction mixture. When the specific antibodies exist in the sample, complement activation triggered by antibody binding on the surface of the antigen-expressing cells may lyse the cells, releasing LDH into the medium. Mouse and rabbit sera hyperimmune to nonstructural protein 1 (NS1) of Japanese encephalitis virus (JEV) lysed NS1-expressing cells in a dose-dependent manner. Evaluations using sera from horses naturally infected with JEV showed that the CDC assay had quantitative correlation and qualitative agreement with previously established NS1 antibody-detecting immunostaining and ELISA methods. The assay method also detected NS1 antibodies in sera of mice 2 days after experimental infection with JEV; specific, but not natural, immunoglobulin M antibodies were detected. Since almost all sera examined in this study showed no nonspecific reactions, the CDC assay was shown to be a reliable method for measuring low levels of specific antibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032598      PMCID: PMC2223849          DOI: 10.1128/CVI.00347-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  21 in total

1.  Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Kyung Min Chung; Grant E Nybakken; Bruce S Thompson; Michael J Engle; Anantha Marri; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 2.  The CD5 B cell.

Authors:  T J Kipps
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

3.  Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination.

Authors:  P Y Shu; L K Chen; S F Chang; Y Y Yueh; L Chow; L J Chien; C Chin; T H Lin; J H Huang
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

4.  Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1.

Authors:  J J Schlesinger; M W Brandriss; C B Cropp; T P Monath
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

5.  The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virus.

Authors:  W A Boere; B J Benaissa-Trouw; T Harmsen; T Erich; C A Kraaijeveld; H Snippe
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

6.  Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats.

Authors:  Irene Massari; Alessia Donnini; Katy Argentati; Stefania Straino; Antonella Mangoni; Carlo Gaetano; Claudio Viticchi; Maurizio Capogrossi; Mauro Provinciali
Journal:  Exp Gerontol       Date:  2002-06       Impact factor: 4.032

7.  Prevalence of antibody to Japanese encephalitis virus nonstructural 1 protein among racehorses in Japan: indication of natural infection and need for continuous vaccination.

Authors:  Eiji Konishi; Mizue Shoda; Takashi Kondo
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

8.  Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations.

Authors:  Eiji Konishi; Tomoyuki Suzuki
Journal:  Vaccine       Date:  2002-11-22       Impact factor: 3.641

9.  Epitope-blocking enzyme-linked immunosorbent assay to differentiate west nile virus from Japanese encephalitis virus infections in equine sera.

Authors:  Yoko Kitai; Mizue Shoda; Takashi Kondo; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

10.  Comparison of specific and cross-reactive antigens of alphaviruses on virions and infected cells.

Authors:  D Gates; A Brown; C J Wust
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

View more
  12 in total

1.  Comparison of the effect of the aerobic glycolysis inhibitor dichloroacetate and of the Krebs cycle inhibitor LW6 on cellular and humoral alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Athanasios Mavropoulos; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Biomed Rep       Date:  2017-09-11

Review 2.  Advances in the assessment and control of the effector functions of therapeutic antibodies.

Authors:  Xu-Rong Jiang; An Song; Svetlana Bergelson; Thomas Arroll; Bhavin Parekh; Kimberly May; Shan Chung; Robert Strouse; Anthony Mire-Sluis; Mark Schenerman
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

3.  In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Nikolaos Antoniadis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2017-05-15       Impact factor: 2.370

4.  Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.

Authors:  Gyoung Nyoun Kim; Kunyu Wu; Jiho Patrick Hong; Zain Awamleh; C Yong Kang
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

5.  Complement-dependent cytotoxicity assay for differentiating West Nile virus from Japanese encephalitis virus infections in horses.

Authors:  Yoko Kitai; Takashi Kondo; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2010-03-17

6.  Polyomavirus BK neutralizing activity in human immunoglobulin preparations.

Authors:  Parmjeet S Randhawa; Kristine Schonder; Ron Shapiro; Nousha Farasati; Yuchen Huang
Journal:  Transplantation       Date:  2010-06-27       Impact factor: 4.939

7.  Nonstructural protein 1-specific immunoglobulin M and G antibody capture enzyme-linked immunosorbent assays in diagnosis of flaviviral infections in humans.

Authors:  Day-Yu Chao; Jedhan Ucat Galula; Wen-Fan Shen; Brent S Davis; Gwong-Jen J Chang
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

Review 8.  The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.

Authors:  Jennifer R Brown; Florence Cymbalista; Jeff Sharman; Ira Jacobs; Pilar Nava-Parada; Anthony Mato
Journal:  Oncologist       Date:  2017-12-06

9.  Establishment of an Algorithm Using prM/E- and NS1-Specific IgM Antibody-Capture Enzyme-Linked Immunosorbent Assays in Diagnosis of Japanese Encephalitis Virus and West Nile Virus Infections in Humans.

Authors:  Jedhan U Galula; Gwong-Jen J Chang; Shih-Te Chuang; Day-Yu Chao
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

10.  Assessment of Humoral Alloimmunity in Mixed Lymphocyte Reaction.

Authors:  Georgios Pissas; Theodoros Eleftheriadis
Journal:  Bio Protoc       Date:  2019-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.